Skip to content
Clinical Trials – home

Drammen Sykehus

Research site

Norway Dronninggata 28, 3004 Drammen, Norway

  • 8 trials recruiting
  • Atrial fibrillation · Chronic kidney disease · Lung disorder
  • Adults and children

About Specializations

Drammen Sykehus in Drammen, Norway specialises in clinical trials of conditions such as Atrial fibrillation, Chronic kidney disease, Lung disorder, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

Drammen Sykehus is involved in clinical research on atherosclerotic cardiovascular disease and atrial fibrillation, with studies focused on preventing major heart and stroke events and improving protection against clot-related complications.

  • Testing new approaches to reduce the risk of heart attack, stroke, and cardiovascular death
  • Evaluating whether anticoagulation can better prevent stroke and systemic embolism in transient atrial fibrillation
  • Studying treatment strategies for patients with stress-related atrial fibrillation to improve long-term outcomes

These trials aim to strengthen cardiovascular prevention and refine treatment choices for people at high risk of serious vascular events.

Neoplasms

The site is also active in cancer research, especially for breast cancer and pancreatic ductal cancer, where investigators are exploring ways to improve treatment effectiveness and reduce disease progression.

  • Assessing new treatment combinations for hormone receptor positive and triple negative breast cancer
  • Comparing therapies to improve survival outcomes after breast cancer surgery
  • Studying ways to prevent thrombosis in pancreatic cancer patients receiving supportive care

This research reflects a strong interest in both oncology and supportive strategies that may improve patient outcomes and safety.

Nervous System Diseases

Clinical trials at Drammen Sykehus include work in multiple sclerosis and acute ischemic stroke, with a focus on treatment safety, symptom control, and better recovery after neurological events.

  • Evaluating safety and long-term tolerability of treatments for relapsing multiple sclerosis
  • Studying whether new add-on therapy can support disease control in people with multiple sclerosis
  • Comparing stroke treatment strategies to improve early neurological recovery

These studies support ongoing progress in neurology, especially for conditions where timely and effective treatment can make a major difference.

Musculoskeletal Diseases

Research in rheumatoid arthritis at this hospital focuses on maintaining stable disease control and reducing flare-ups for people living with chronic inflammatory joint disease.

  • Testing whether proactive monitoring can improve control of rheumatoid arthritis
  • Exploring treatment management strategies for patients receiving biologic therapy

This work is designed to improve everyday care in rheumatology by helping clinicians tailor treatment more effectively.

Nutritional and Metabolic Diseases

The site contributes to studies in overweight and obesity, with research aimed at supporting weight reduction and healthier metabolic outcomes alongside lifestyle counseling.

  • Evaluating whether a new therapy can help achieve meaningful weight loss
  • Comparing weight reduction outcomes against placebo in people with excess body weight

These trials reflect a practical focus on metabolic health and long-term weight management.

Otorhinolaryngologic Diseases

Clinical research at the site also includes hearing disorders, particularly idiopathic sudden sensorineural hearing loss, where investigators are examining ways to improve recovery after sudden hearing loss.

  • Testing whether an added treatment can improve hearing outcomes
  • Comparing recovery results between standard care and supportive therapy

This research aims to improve ear and hearing care by finding better options for patients with sudden auditory loss.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Dronninggata 283004 DrammenNorway
Recruiting now
8 trials
Conditions studied
21

More sites in DrammenNorway

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

18 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study on Clopidogrel and Dalteparin Sodium for Preventing Blood Clots in Pancreatic Cancer Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Clopidogrel
  • Sponsor:Akershus University Hospital

Study on the Effectiveness of Tenecteplase in Patients with Acute Ischemic Stroke Taking Rivaroxaban, Apixaban, or Edoxaban

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Oslo University Hospital HF

Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Hamilton Health Sciences Corporation

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Apixaban for Preventing Stroke in Patients with Atrial Fibrillation and Stage 5 Chronic Kidney Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Karolinska University Hospital

Study of Hyperbaric Oxygen Therapy Combined with Standard Treatment for Patients with Sudden Hearing Loss

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nitrous Oxide
  • Sponsor:Helse Bergen HF

Maintenance versus tapered TNF‑alpha inhibitor therapy (golimumab, etanercept, adalimumab) in children and adolescents with juvenile idiopathic arthritis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Oslo University Hospital HF

Obesity+1

Not recruiting

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.